Clinical Trial

Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The goal of Phase 1b is to establish the safety of asciminib in combination with FLAG-Ida and venetoclax in patients with CML-MBP, CML-LBP, and Ph+ AML. The goal of Phase 2 is to learn if asciminib in combination with FLAG-Ida and venetoclax can help to control the disease.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2026-05-18; most recent amendment 2026-06-04.
Trial Details
NCT Number NCT07604233
Lead Sponsor M.D. Anderson Cancer Center
Conditions Myeloid Leukemia
Enrollment 30 participants
Start Date 2026-11-30
Primary Completion 2031-06-03 (estimated)
Study Completion 2033-06-03 (estimated)
Updated on ClinicalTrials.gov 2026-06-08